

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**WAI YUEN TONG MEDICINE HOLDINGS LIMITED**  
**(位元堂藥業控股有限公司\*)**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 897)**

**INSIDE INFORMATION**  
**PROFIT ALERT**

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules and Inside Information Provisions under Part XIVA of the SFO.

The Board would like to inform the shareholders and potential investors of the Company that based on the preliminary review of the draft unaudited consolidated management accounts of the Group for the financial year ended 31 March 2023 and the information currently available to the Board, the Group is expected to record a loss attributable to owners of the parent of not more than HK\$35 million for the financial year ended 31 March 2023 as compared with a loss attributable to owners of the parent for the financial year ended 31 March 2022 of approximately HK\$108.9 million as published in the Company's 2022 annual report.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

This announcement is made by Wai Yuen Tong Medicine Holdings Limited (位元堂藥業控股有限公司\*) (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

The board of directors (the “**Board**” or the “**Directors**”) of the Company would like to inform the shareholders and potential investors of the Company that based on the preliminary review of the draft unaudited consolidated management accounts of the Group for the financial year ended 31 March 2023 and the information currently available to the Board, the Group is expected to record a loss attributable to owners of the parent of not more than HK\$35 million for the financial year ended 31 March 2023 as compared with a loss attributable to owners of the parent for the financial year ended 31 March 2022 of approximately HK\$108.9 million as published in the Company’s 2022 annual report.

Such reduction in loss is mainly attributable to the combined effect of (i) increase in gross profit generated from the production and sale of pharmaceutical and health food products; (ii) decrease in fair value losses on investment properties; (iii) decrease in fair value losses on financial assets; and (iv) decrease in loss on disposal/redemption of financial assets, as partially offset by the absence of compensation income from litigation judgement for the financial year ended 31 March 2023.

As the Company is still in the course of finalizing its annual results for the financial year ended 31 March 2023, the information contained in this announcement is only based on the preliminary review of the draft unaudited consolidated management accounts of the Group for the financial year ended 31 March 2023 and the information currently available to the Board, and is subject to finalization of valuation results of properties and financial instruments by independent professional valuers, which have yet to be confirmed, reviewed or audited by the independent auditors or the audit committee of the Company. Details of the performance of the Group for the financial year ended 31 March 2023 will be disclosed in the annual results announcement of the Company which is expected to be published by end of June 2023 in accordance with the requirements under the Listing Rules.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**WAI YUEN TONG MEDICINE HOLDINGS LIMITED**  
(位元堂藥業控股有限公司\*)  
**Tang Ching Ho**  
*Chairman and Managing Director*

Hong Kong, 9 June 2023

*As at the date of this announcement, the executive directors of the Company are Mr. Tang Ching Ho, Ms. Tang Wai Man and Ms. Law Man Yee, Anita, and the independent non-executive directors of the Company are Mr. Leung Wai Ho, Mr. Siu Man Ho, Simon, Mr. Cho Wing Mou and Mr. Li Ka Fai, David.*

\* For identification purpose only